Everything below concerns c-Met signaling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
After the conclusion of the visit, Trump posted on Truth Social, where he confirmed the two leaders would meet again at the APEC China 2026 in Shenzhen in November and the 2026 G20 Miami summit in December. He said "Much has been, and will be, accomplished. I look forward to our next meeting!" On September 26, the government of China announced that the leaders of China and the United States reached an eight-point consensus, including:
=== Hospitals === Most clinical teaching takes place in facilities operated by UNC Health, primarily within the UNC Medical Center complex at the southern tip of the UNC campus. The complex comprises five healthcare facilities collectively known as UNC Hospitals, including North Carolina Memorial Hospital, North Carolina Children’s Hospital, North Carolina Women’s Hospital, North Carolina Neurosciences Hospital, and North Carolina Cancer Hospital. In 2024, the North Carolina Surgical Hospital was opened, featuring 26 new surgical spaces and 80 inpatient rooms. Together, these facilities offer over 1,000 inpatient beds and are ranked as the 2nd best hospital in the state of North Carolina. Additional hospitals and outpatient clinics in the area are also used for training, including the Ambulatory Care Center, the Family Medicine Building, UNC Hillsborough, and UNC Chatham. During the Application Phase (third year) of the school's MD program, students will be matched into one of six regions located across the state of North Carolina to complete their clinical clerkships at local facilities, including:
== See also == List of investigational drugs List of investigational generalized anxiety disorder drugs List of investigational panic disorder drugs List of investigational post-traumatic stress disorder drugs List of investigational anxiety disorder drugs List of investigational autism and pervasive developmental disorder drugs List of investigational aggression drugs
==== P-Glycoprotein inhibition ==== Bicalutamide, as well as enzalutamide, have been found to act as inhibitors of P-glycoprotein efflux and ATPase activity. This action may reverse docetaxel resistance in prostate cancer cells by reducing transport of the drug out of these cells.
== Selected publications == McGuire, Darren K.; Shih, W.J.; Cosentino, F.; et al. (2021). "Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis". JAMA Cardiology. 6 (2): 148–158. doi:10.1001/jamacardio.2020.4511. PMC 7542529. PMID 33031522. McGuire, Darren K.; Busui, R.P.; Deanfield, J.; et al. (2023). "Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial". Diabetes, Obesity and Metabolism. 26 (2): 482–494. doi:10.1111/dom.15334. PMID 37846527. McGuire, Darren K.; Marx, N.; Mulvagh, S.L.; et al. (2025). "Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes". New England Journal of Medicine. 392 (20): 2001–2012. doi:10.1056/NEJMoa2501006. PMID 40162642. McGuire, Darren K.; Pagidipati, N.J. (2021). "GLP-1 receptor agonists: from antihyperglycaemic to cardiovascular drugs". The Lancet Diabetes & Endocrinology. doi:10.1016/S2213-8587(21)00155-4 (inactive 15 April 2026).{{cite journal}}: CS1 maint: DOI inactive as of April 2026 (link) Patel, Krishna V.; De Albuquerque Rocha, Natasha; McGuire, Darren K. (2017). "Diabetes medications and cardiovascular outcome trials: Lessons learned". Cleveland Clinic Journal of Medicine. 6 (2): 148–158. doi:10.1001/jamacardio.2020.4511. PMC 7542529. PMID 33031522. McGuire, Darren K.; D'Alessio, D.; Nicholls, S.J.; et al. (2022).
Sources: en.wikipedia.org
=== Interaction with lipid membranes === Experimental evidence has been collected on the interaction of alpha-synuclein with membrane and its involvement with membrane composition and turnover. Yeast genome screening has found that several genes that deal with lipid metabolism and mitochondrial fusion play a role in alpha-synuclein toxicity. Conversely, alpha-synuclein expression levels can affect the viscosity and the relative amount of fatty acids in the lipid bilayer. Alpha-synuclein is known to directly bind to lipid membranes, associating with the negatively charged surfaces of phospholipids. Alpha-synuclein forms an extended helical structure on small unilamellar vesicles. A preferential binding to small vesicles has been found. The binding of alpha-synuclein to lipid membranes has complex effects on the latter, altering the bilayer structure and leading to the formation of small vesicles. Alpha-synuclein has been shown to bend membranes of negatively charged phospholipid vesicles and form tubules from large lipid vesicles. Using cryo-EM it was shown that these are micellar tubes of ~5-6 nm diameter. Alpha-synuclein has also been shown to form lipid disc-like particles similar to apolipoproteins. EPR studies have shown that the structure of alpha synuclein is dependent on the binding surface. The protein adopts a broken-helical conformation on lipoprotein particles while it forms an extended helical structure on lipid vesicles and membrane tubes. Studies have also suggested a possible antioxidant activity of alpha-synuclein in the membrane.
Later in the eighteenth century the crown sought to decrease the privileges (fueros) of the clergy, restricting clerical authority to spiritual matters and undermining the power of parish priests, who often acted as agents of the crown in rural parishes. By desacralizing power and frontal attacks on the clergy, the crown, according to William B. Taylor, undermined its own legitimacy, since parish priests had been traditionally the "natural local representatives of their Catholic king." In the economic sphere, the crown sought to gain control over church revenues. The Church functioned as one of the largest economic institutions within colonial Spanish America. It owned and retained jurisdiction over large amounts of land, which the crown wanted for itself because of the economic value which could be derived from the land. Moreover, by taking that land for itself, the Crown had the opportunity to cut down the physical presence of the Church to further weaken its ideological and social role within local colonial communities. In a financial crisis of 1804, the crown attempted to call in debts owed the church, mainly in the form of mortgages for haciendas owned by the elites. The Act of Consolidation simultaneously threatened the wealth of the church, whose capital was mainly lent for mortgages, as well as threatening the financial well-being of elites, who depended on mortgages for acquiring and keeping their estates. Shortening the repayment period meant many elites were faced with bankruptcy.
=== Cobaltocene and derivatives === Cobaltocene, Co(C5H5)2, is a metallocene, the cobalt analogue of ferrocene. It is a dark purple solid. Cobaltocene has 19 valence electrons, one more than usually found in organotransition metal complexes, such as its very stable relative, ferrocene, in accordance with the 18-electron rule. This additional electron occupies an orbital that is antibonding with respect to the Co–C bonds. Consequently, many chemical reactions of Co(C5H5)2 are characterized by its tendency to lose this "extra" electron, yielding a very stable 18-electron cation known as cobaltocenium. Many cobaltocenium salts coprecipitate with caesium salts, and cobaltocenium hydroxide is a strong base that absorbs atmospheric carbon dioxide to form cobaltocenium carbonate. Like the alkali metals, cobaltocene is a strong reducing agent, and decamethylcobaltocene is stronger still due to the combined inductive effect of the ten methyl groups. Cobalt may be substituted by its heavier congener rhodium to give rhodocene, an even stronger reducing agent. Iridocene (involving iridium) would presumably be still more potent, but is not very well-studied due to its instability.
When adhered to a surface, neutrophil granulocytes have an average diameter of 12–15 micrometers (μm) in peripheral blood smears. In suspension, human neutrophils have an average diameter of 8.85 μm. With the eosinophil and the basophil, they form the class of polymorphonuclear cells, named for the nucleus's multilobulated shape (as compared to lymphocytes and monocytes, the other types of white cells). The nucleus has a characteristic lobed appearance, the separate lobes connected by chromatin. The nucleolus disappears as the neutrophil matures, which is something that happens in only a few other types of nucleated cells. Up to 17% of female human neutrophil nuclei have a drumstick-shaped appendage which contains the inactivated X chromosome. In the cytoplasm, the Golgi apparatus is small, mitochondria and ribosomes are sparse, and the rough endoplasmic reticulum is absent. The cytoplasm also contains about 200 granules, of which a third are azurophilic. Neutrophils will show increasing segmentation (many segments of the nucleus) as they mature. A normal neutrophil should have 3–5 segments. Hypersegmentation is not normal but occurs in some disorders, most notably vitamin B12 deficiency. This is noted in a manual review of the blood smear and is positive when most or all of the neutrophils have 5 or more segments.
=== Attachment to tendons === Muscles attach to tendons in a complex interface region known as the musculotendinous junction, also known as the myotendinous junction, an area specialised for the primary transmission of force. At the muscle-tendon interface, force is transmitted from the sarcomeres in the muscle cells to the tendon. Muscles and tendons develop in close association, and after their joining at the myotendinous junction they constitute a dynamic unit for the transmission of force from muscle contraction to the skeletal system.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.